VivoSeq
Oncology

Leukemia, Acute Lymphoblastic

8

Pipeline Programs↗

0

Active Trials↗

3

Companies Involved↗

Leukemia, Acute Lymphoblastic is an early-stage landscape with 8 programs across 3 companies. The most active players are Amgen, Hikma Pharmaceuticals LLC, Alnylam Pharmaceuticals. 8 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

33/100

Pipeline Velocity

0/100

Mech. Concentration

25/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Amgen logo

Amgen

4 programs

Phase 3H

Hikma Pharmaceuticals LLC

1 program

Phase 3Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 38

Blinatumomab

Amgen

Dexamethasone

Aspen Global Incorporated

Vincrisitne

Amgen

Daunorubicin

Hikma Pharmaceuticals LLC

Methotrexate

Alnylam Pharmaceuticals

Approved
No programs

Analysis

Modality Breakdown

63%

Small molecule

5 of 8 classified programs — the dominant modality here.

38%ALL OTHERSProtein / enzyme225%Monoclonal antibody113%

Small molecule leads; the ring shows all 8 classified programs, each share of the total. Modality classified for 100% of 8 pipeline programs.

Analysis

Trial Status

2

clinical trials

Completed2 · 100%

Clinical Trials

Trial Activity

Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALL
Completed·Amgen logoAmgen·Phase 3·NCT02393859·111 enrolled
CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL
Completed·National Cancer Institute (NCI)·N/A·NCT05440409·57 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)